Login to Your Account



Clinic Roundup


Friday, February 11, 2011
Novartis AG, of Basel, Switzerland, said data from the Phase III RADIANT-3 trial showed that mTOR inhibitor Afinitor (everolimus) plus best supportive care more than doubled progression-free survival vs. placebo plus best supportive care in patients with advanced pancreatic neuroendocrine tumors. Data were published in The New England Journal of Medicine.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription